Avenacy Announces Launch of Tranexamic Acid Injection, USP in the U.S. Market
Rubicon Generic Tranexamic Acid Receives Approval in US
Gland Pharma`s Generic Tranexamic Acid Receives Approval in the U.S
Enforcement Report - Week of October 12, 2022
Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures HY-004 provides a new treatment alternative for use in...
BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that on August 23, 2021 it entered into a license agreement with Pierre Fabre Farma de Mexico, S.A. de C.V. (Pierre Fabre), a subsidiary of the Pierre Fabre group which distribute products in over 100 countries around the world. Under the agreement, Amring granted to Pierre Fabre an exclusive royalty-bearing license to exploit and commercialize LYSTEDA (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB) in Mexico.
Received CEP approval for Tranexamic Acid
Tranexamic Acid Mouthwash Failure update: Presented at ISTH
The Food and Drug Administration (FDA) has received reports of tranexamic acid injection being erroneously administered intrathecally in the perioperative setting instead of the intended intrathecal anesthetic (eg, bupivacaine injection) for neuraxial anesthesia.